US$ 23.71
glp-1 vagus nerve JCI Recent advances in targeting obesity,
Description
Notably, Mounjaro expected to receive FDA approval for weight loss in 2024

Both have FDA approval specifically for weight management

Medication selection also depends on health history, side-effect tolerance, diabetes status, pregnancy plans, medication interactions, insurance, cost, availability, and individual treatment goals

Dysglycemia Shapes Visceral Adipose Tissues Response to GIP, GLP-1 and Glucagon in Individuals with Obesity

[DOI] [PubMed] [Google Scholar] 132.Wu Y.C., Wang W.T., Lee S.S., Kuo Y.R., Wang Y.C., Yen S.J
